Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Artem Shendetskii
Artem Shendetskii

Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study

Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study
Nurix launches CLL drug trial

Nurix Therapeutics has launched its DAYBREAK-CLL-201 clinical trial to evaluate bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

The study focuses on the scientific rationale and design aimed at addressing treatment challenges in difficult-to-treat CLL cases. The company’s effort reflects ongoing innovation in hematology and underlines the importance of advancing new therapeutic options for patients.

Nurix Therapeutics has previously built momentum with its investigational oral BTK degrader bexobrutideg in trials for relapsed or refractory CLL, according to a recent update. The company also announced a strategic partnership with Roche to accelerate the bexobrutideg program. Both developments support Nurix’s ongoing efforts in CLL drug development.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

From airline tickets to Ferraris: What can you buy with crypto?
  • By Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
Editors' Picks
Apartment or Bitcoin: Choosing a safe haven for your wealth
  • By Pavlo Kot
  • 07.11.2026
Apartment or Bitcoin: Choosing a safe haven for your wealth
Editors' Picks
CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?
  • By Dmytro Kharkov
  • 06.11.2026
CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?
Editors' Picks
All Editors' Top Picks

Latest Nurix News

Nurix Therapeutics to present new Phase 1a1b study data on BTK degrader bexobrutideg in CLLSLL
  • By Ksenia Gerey
  • 05.11.2026
Nurix Therapeutics to present new Phase 1a1b study data on BTK degrader bexobrutideg in CLLSLL
Companies
#Nurix
BTK degrader clinical program progresses as Nurix Therapeutics delivers Q3 2026 results
  • By Igor Krasulya
  • 12.10.2026
BTK degrader clinical program progresses as Nurix Therapeutics delivers Q3 2026 results
Companies
#Nurix
Nurix Therapeutics enrolls first patient in Phase 1b2 trial of oral BTK degrader for CLL
  • By Alena Volkova
  • 07.10.2026
Nurix Therapeutics enrolls first patient in Phase 1b2 trial of oral BTK degrader for CLL
Companies
#Nurix
All Nurix News
  • Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
  • Pavlo Kot
  • 07.11.2026
Apartment or Bitcoin: Choosing a safe haven for your wealth
  • Dmytro Kharkov
  • 06.11.2026
CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?
  • Anastasiia Chabaniuk
  • 06.11.2026
Italy embraces blockchain, but remains wary of cryptocurrencies
  • Mikhail Vnuchkov
  • 06.11.2026
From Wall Street to Bitcoin: A wave of panic sweeps across markets
  • Hanna Syniavska
  • 4 min ago
Ultrasound money thesis echoes Venezuela's bolivar redenomination, Fernando Nikolic notes
  • Yaroslav Dmytrenko
  • 15 min ago
Financial and marital challenges can affect anyone, David Schwartz notes
  • Oksana Koneva
  • 1 hour ago
Adam Khoo: CEO exit risk is main concern for company with no clear successor
  • Eugene Komchuk
  • 1 hour ago
Stephan Livera: Multi-sig poised to become standard for Bitcoin life savings
  • Hanna Syniavska
  • 1 hour ago
Long-term Bitcoin holders experience major gains, Fred Krueger notes
Top News
  • Andreas Kristo
  • 18 hours ago
Taiwan slashes short-selling limit from 30% to 3% after market rout
Taiwan slashes short-selling limit from 30% to 3% after market rout
  • Mélissa Bac
  • 19 hours ago
Asian markets rotate beyond semiconductors as AI stocks lose momentum
Asian markets rotate beyond semiconductors as AI stocks lose momentum
  • Jainam Mehta
  • 20 hours ago
Berkshire Hathaway buybacks hit record $9.6B as Greg Abel shifts capital strategy
Berkshire Hathaway buybacks hit record $9.6B as Greg Abel shifts capital strategy
  • Pavlo Kot
  • Yesterday
From airline tickets to Ferraris: What can you buy with crypto?
From airline tickets to Ferraris: What can you buy with crypto?
  • Mikhail Vnuchkov
  • Yesterday
Wall Street analysts urge investors to buy stocks after U.S. market rout
Wall Street analysts urge investors to buy stocks after U.S. market rout
Live News
  • Pavlo Kot
  • Now
Binance hackers still hold $3.1 billion in cryptocurrency after attack
  • Mykhailo Ihnatenko
  • Now
AMD stock attempts recovery after sharp sell-off wipes out post-earnings gains
  • Anton Kharitonov
  • Now
EUR/USD slips toward 1.1170 as dollar demand rises ahead of NFP
  • Mykhailo Ihnatenko
  • Now
Ethereum price falls toward $2,200 as long liquidations hit $1.12B
  • Eugene Komchuk
  • Now
Google could acquire a stake in TeraWulf's AI project
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers